Please see full Prescribing Information in pocket.

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Risk of Implant Migration:

Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration.

Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

YUTIQ® Reimbursement and Diagnosis Codes

Call EyePoint Assist™ for more information: 1-833-393-7646; Option 2

INDICATIONS AND USAGE

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

ICD-10 Codes for Non-infectious (NI) Intermediate, Posterior and Panuveitis

Below you will find ICD-10 codes for non-infectious intermediate and posterior uveitis, as well as multiple subtypes of posterior uveitis.

The codes included in this chart are not intended to encourage or suggest a use of any drug that is inconsistent with FDA-approved use. Please refer to the current policy for the latest codes since these codes are subject to change.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS
Internuclear Injection-related Effects: Internuclear injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypopyon has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

ADVERSE REACTIONS

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Please see full Prescribing Information in pocket.
Intravitreal Injections, including those with YUTIQ, have been associated with endophthalmitis, posterior vitreitis, and retinal detachments. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including varicella, mycobacterial infections and fungal diseases. The codes included in this chart are not intended to encourage or suggest a use of any drug that is inconsistent with FDA-approved use.

Below you will find ICD-10 codes for non-infectious intermediate and panuveitis, as well as multiple subtypes of posterior uveitis. Please refer to the current policy for the latest codes since these codes are subject to change.

INDICATIONS AND USAGE
YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

ICD-10 Codes for Non-infectious (NI) Intermediate, Posterior and Panuveitis

Unspecified eye
Right eye
Left eye
Bilateral

Unspecified eye
Disseminated chorioretinal inflammation (chorioretinitis/choroiditis) posterior pole
Right eye
Left eye
Bilateral

Disseminated chorioretinal inflammation (chorioretinitis/choroiditis) peripheral
Right eye
Left eye
Bilateral

Disseminated chorioretinal inflammation, generalized
Right eye
Left eye
Bilateral

Unspecified eye
Focal chorioretinal inflammation, juxtapapillary
Right eye
Left eye
Bilateral

Unspecified eye
Focal chorioretinal inflammation, macular or paramacular
Right eye
Left eye
Bilateral

Unspecified eye
Unspecified disseminated chorioretinal inflammation (chorioretinitis/choroiditis)
Right eye
Left eye
Bilateral

Unspecified eye
Unspecified disseminated chorioretinal inflammation (chorioretinitis/choroiditis) posterior pole
Right eye
Left eye
Bilateral

Other chorioretinal inflammations
Other chorioretinal inflammations, right eye
Other chorioretinal inflammations, left eye
Other chorioretinal inflammations, bilateral

Unspecified chorioretinal inflammation (chorioretinitis/choroiditis)
Unspecified chorioretinal inflammation, right eye
Unspecified chorioretinal inflammation, left eye
Unspecified chorioretinal inflammation, bilateral

Adverse reactions
In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

IMPORTANT SAFETY INFORMATION (cont’d)

YUTIQ® Reimbursement and Diagnosis Codes

Call EyePoint AssistSM for more information: 1-833-393-7646; Option 2

HCPCS
J7314
Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg

10-digit NDC
71879-0136-01
71879-136-01
71879-036-01

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg

©2019, EyePoint Pharmaceuticals, Inc. All rights reserved.
480 Pleasant Street, Suite B300, Watertown, MA 02472
YUTIQ® is a registered trademark and the YUTIQ logo and the EyePoint logo are trademarks and EyePoint Assist is a service mark of EyePoint Pharmaceuticals, Inc.

9/2019 US-YUT-1900089

YUTIQ® is not indicated for the treatment of acute or subacute intraocular inflammation affecting the anterior segment of the eye.